---
title: "Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment"
description: "Astria Therapeutics is conducting a Phase 3 trial, ORBIT-EXPANSE, to evaluate the long-term safety and efficacy of navenibart for hereditary angioedema (HAE). The trial focuses on personalized dosing "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262964791.md"
published_at: "2025-10-27T21:55:35.000Z"
---

# Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment

> Astria Therapeutics is conducting a Phase 3 trial, ORBIT-EXPANSE, to evaluate the long-term safety and efficacy of navenibart for hereditary angioedema (HAE). The trial focuses on personalized dosing options and involves a non-randomized, parallel intervention model. The study began on September 30, 2025, with ongoing updates indicating progress. Successful outcomes may positively impact Astria's stock performance and enhance its competitive position in the HAE treatment market. Further details are available on the ClinicalTrials portal.

Astria Therapeutics, Inc. is conducting a Phase 3 trial titled ‘A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema – ORBIT-EXPANSE.’ The study aims to assess the long-term safety and efficacy of navenibart in individuals with hereditary angioedema (HAE), focusing on providing personalized dosing options to optimize treatment outcomes.

The intervention being tested is navenibart, a drug administered via subcutaneous injection. It is designed to manage and prevent symptoms associated with hereditary angioedema, offering various dosing regimens to cater to individual patient needs.

This interventional study is non-randomized with a parallel intervention model. It involves no masking, meaning all participants receive navenibart, but they are blinded to their specific treatment arm for a certain period. The primary purpose of the study is prevention.

The study began on September 30, 2025, with its primary completion date yet to be determined. The most recent update was submitted on October 1, 2025, indicating ongoing progress and adjustments as needed.

The update on this study could influence Astria Therapeutics’ stock performance positively, as successful outcomes may enhance investor confidence and market position. Given the competitive landscape in the treatment of hereditary angioedema, advancements in this trial could position Astria favorably against competitors.

The study is currently ongoing, with further details available on the ClinicalTrials portal.

### Related Stocks

- [ATXS.US - Astria Therapeutics](https://longbridge.com/en/quote/ATXS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Astria Therapeutics announces new clinical trial results and Phase 3 study for navenibart in hereditary angioedema | Astria Therapeutics Inc. announced it will present data on navenibart at the CSACI 80th Anniversary Scientific Meeting f | [Link](https://longbridge.com/en/news/260449340.md) |
| Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema | Astria Therapeutics Inc. will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart for here | [Link](https://longbridge.com/en/news/263738231.md) |
| A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight | BioCryst Pharmaceuticals (BCRX) has gained attention following the announcement of nine hereditary angioedema presentati | [Link](https://longbridge.com/en/news/275698599.md) |
| Tectonic Therapeutic Hosts Virtual KOL Event Showcasing TX2100 for Hereditary Hemorrhagic Telangiectasia | Tectonic Therapeutic Inc. (NASDAQ: TECX) will host a virtual KOL event on TX2100, a new treatment for Hereditary Hemorrh | [Link](https://longbridge.com/en/news/275655792.md) |
| BioCryst Unveils Positive New HAE Data for ORLADEYO and Navenibart at AAAAI 2026 | BioCryst Pharmaceuticals Inc. will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAA | [Link](https://longbridge.com/en/news/275599962.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.